Collaboration, License and Other Agreements - Pfizer Collaboration (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
License and other agreements
Revenue		$ 318,852	$ 43,823
Collaboration and other revenue
License and other agreements
Revenue		195,262	$ 0
Pfizer
License and other agreements
Number of shares sold in transaction (in shares)	2,022,581
Proceeds from sale of stock	$ 350,000
Estimated fair value of shares issued	252,000
Share purchase premium received	98,000
Pfizer | Collaborative arrangement
License and other agreements
Upfront payment received	150,000
Share purchase premium received	98,000
Eligible contingent payments receivable per agreement for sales-based milestones	740,000
Contract liability	$ 53,611	52,738
Contract liability, current		21,763
Contract liability, noncurrent		30,975
Pfizer | Collaborative arrangement | Maximum
License and other agreements
Agreement term after first commercial sale	10 years
Pfizer | Collaborative arrangement | Collaboration and other revenue
License and other agreements
Revenue		194,389
Revenue recognized that was previously in contract liability		$ 873